Autho (Year) | Country | Participants | Type of intervention (manufacturers/companies) | Treatment group ICIs rate | Type of control | Control group ICIs rate |
---|---|---|---|---|---|---|
Savitz and Malis.(1976) [11] | USA | Craniotomy | 200 mg Clindamycin IV (N/A) | 1/60 | No prophylactic antibiotic | 9/50 |
Geraghty et al.(1984) [12] | Ireland | Craniotomy+Burr hole | 1 g Vancomycin IV (N/A) | 0/72 | No prophylactic antibiotic | 5/67 |
Young et al.(1987) [13] | USA | Craniotomy+Stereotaxic procedures+Shunt placement | 1 g Cefazolin IV (N/A) | 3/286 | No prophylactic antibiotic | 13/301 |
Blomstedt et al.(1988) [14] | Finland | Supratentorial+suboccipital Craniotomy | 1 g Vancomycin IV (N/A) | 3/169 | No prophylactic antibiotic | 14/191 |
Bullock et al.(1988) [15] | South Africa | Craniotomy+VP shunt | 2 g Piperacillin sodium IV (N/A) | 2/141 | Placebo | 10/159 |
Van Ek et al.(1988) [16] | Netherlands | Craniotomy with Bone flap+subdual drainage+insertion+interval shunt+ommaya reseroir | 1 g Cloxacillin IV (N/A) | 6/183 | Placebo | 20/195 |
Blum et al.(1989) [17] | Germany | Shunt | 50 mg/kg Cefazedone IV (RefosporinR, E. Merck) | 3/50 | No prophylactic antibiotic | 7/50 |
Djindjian et al.(1990) [18] | France | Cerebral tumor+Meningioma+Vascular+Posterior fossa+stereotactic | 1 g Oxacillin IV (N/A) | 1/148 | Placebo | 7/153 |
Gaillard et al.(1991) [19] | Germany | Craniotomy | 2 g Cefotiam IV (N/A) | 12/356 | Placebo | 32/355 |
Mindermann et al.(1993) [20] | Switzerland | Craniotomy+Posterior fossa+Cranioplast+Ventricular-peritoneal shunting | 500 mg Fusidic acid IV (Leo Pharmaceutical Products, Zuirich, Switzerland) | 1/41 | Placebo | 4/44 |
Huang W. et al.(2009) [21] | China | Craniotomy | 500 mg Vancomycin IV (Eli Lilly Japan K. K, Seishin Laboratories) | 1/92 | No prophylactic antibiotic | 5/51 |